Windtree Therapeutics, Inc. (WINT) analyst actions
Rating and price-target actions on WINT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the WINT overview →
1 measured WINT analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 | Press release | +0.03% | -5.92% |
Keep exploring
More WINT: earnings → · SEC filings → · WINT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 208 | -0.32% | 48% |
| Journey Medical Corporation (DERM) | 208 | 0.00% | 50% |
| Cronos Group Inc (CRON_TSE) | 206 | +0.15% | 50% |
| Pediatrix Medical Group, Inc. (MD) | 206 | +0.02% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.